On this episode, we’ll be talking about an FDA approval for uveal melanoma, as well as the efficacy of PD-1 inhibition in patients with resectable liver cancer.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Tebentafusp-tebn for the Treatment of Unresectable or Metastatic Uveal Melanoma

Neoadjuvant Cemiplimab-rwlc for Patients With Resectable Hepatocellular Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.